- Home
- WGS vs AGIO Comparison
WGS vs AGIO Comparison
Compare WGS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGS
- AGIO
- Stock Information
- Founded
- WGS 2017
- AGIO 2007
- Country
- WGS United States
- AGIO United States
- Employees
- WGS N/A
- AGIO N/A
- Industry
- WGS Retail: Computer Software & Peripheral Equipment
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- WGS Technology
- AGIO Health Care
- Exchange
- WGS Nasdaq
- AGIO Nasdaq
- Market Cap
- WGS 2.4B
- AGIO 2.1B
- IPO Year
- WGS N/A
- AGIO 2013
- Fundamental
- Price
- WGS $122.04
- AGIO $36.30
- Analyst Decision
- WGS Strong Buy
- AGIO Buy
- Analyst Count
- WGS 7
- AGIO 6
- Target Price
- WGS $102.14
- AGIO $57.00
- AVG Volume (30 Days)
- WGS 579.2K
- AGIO 771.2K
- Earning Date
- WGS 10-28-2025
- AGIO 10-30-2025
- Dividend Yield
- WGS N/A
- AGIO N/A
- EPS Growth
- WGS N/A
- AGIO N/A
- EPS
- WGS 0.05
- AGIO 11.13
- Revenue
- WGS $362,321,000.00
- AGIO $40,875,000.00
- Revenue This Year
- WGS $35.84
- AGIO $28.19
- Revenue Next Year
- WGS $18.46
- AGIO $152.14
- P/E Ratio
- WGS $2,541.32
- AGIO $3.27
- Revenue Growth
- WGS 48.70
- AGIO 30.57
- 52 Week Low
- WGS $35.88
- AGIO $23.42
- 52 Week High
- WGS $136.00
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- WGS 52.27
- AGIO 46.53
- Support Level
- WGS $120.55
- AGIO $34.97
- Resistance Level
- WGS $129.25
- AGIO $37.18
- Average True Range (ATR)
- WGS 5.28
- AGIO 1.59
- MACD
- WGS -2.01
- AGIO -0.20
- Stochastic Oscillator
- WGS 9.64
- AGIO 42.86
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.